Auven Therapeutics
Auven Therapeutics is a private equity company established in 2007, headquartered in Saint Thomas, Virgin Islands, that specializes in the healthcare sector. The company focuses on acquiring controlling ownership of promising therapeutic products or platforms, enhancing their value through global development programs, and subsequently selling them as clinically and commercially validated products to established pharmaceutical firms. Auven Therapeutics maintains a diversified portfolio that includes biologic and small molecule therapeutic candidates aimed at addressing significant unmet medical needs in areas such as cancer, ophthalmic conditions, women’s health, and orphan diseases. The company holds ownership or a controlling interest in various therapeutic assets, including those of ADC Therapeutics, Spirogen, Resolvyx, and Kiacta, alongside minority investments in Kolltan and Sprout Pharmaceuticals. Its drug development operations are managed from locations in Lausanne, Switzerland, New York, USA, and Hamilton, Bermuda.
Top Stages
10 past transactions
ADC Therapeutics
Series E in 2019
ADC Therapeutics is a clinical-stage biotechnology company focused on developing highly potent and targeted antibody-drug conjugates (ADCs) for treating hematological cancers and solid tumors. Its lead product, ZYNLONTA, is FDA-approved for relapsed or refractory large B-cell lymphoma.
ADC Therapeutics
Series E in 2017
ADC Therapeutics is a clinical-stage biotechnology company focused on developing highly potent and targeted antibody-drug conjugates (ADCs) for treating hematological cancers and solid tumors. Its lead product, ZYNLONTA, is FDA-approved for relapsed or refractory large B-cell lymphoma.
ADC Therapeutics
Series D in 2016
ADC Therapeutics is a clinical-stage biotechnology company focused on developing highly potent and targeted antibody-drug conjugates (ADCs) for treating hematological cancers and solid tumors. Its lead product, ZYNLONTA, is FDA-approved for relapsed or refractory large B-cell lymphoma.
ADC Therapeutics
Series C in 2015
ADC Therapeutics is a clinical-stage biotechnology company focused on developing highly potent and targeted antibody-drug conjugates (ADCs) for treating hematological cancers and solid tumors. Its lead product, ZYNLONTA, is FDA-approved for relapsed or refractory large B-cell lymphoma.
ADC Therapeutics
Series B in 2013
ADC Therapeutics is a clinical-stage biotechnology company focused on developing highly potent and targeted antibody-drug conjugates (ADCs) for treating hematological cancers and solid tumors. Its lead product, ZYNLONTA, is FDA-approved for relapsed or refractory large B-cell lymphoma.
ADC Therapeutics
Series A in 2012
ADC Therapeutics is a clinical-stage biotechnology company focused on developing highly potent and targeted antibody-drug conjugates (ADCs) for treating hematological cancers and solid tumors. Its lead product, ZYNLONTA, is FDA-approved for relapsed or refractory large B-cell lymphoma.
Kolltan Pharmaceuticals
Series B in 2010
Kolltan Pharmaceuticals, Inc. is a clinical-stage biotechnology company founded in 2007 and based in New Haven, Connecticut. The company specializes in the discovery and development of monoclonal antibody drugs that target receptor tyrosine kinases (RTKs), which play a crucial role in various cancers and other diseases. Its lead product candidate, KTN3379, is an antibody targeting the ErbB3 RTK and is currently undergoing Phase I clinical trials for adult patients with advanced solid tumors. Additionally, Kolltan is developing KTN0158, a KIT RTK inhibitor aimed at treating neurofibromatosis type 1 and other inflammatory conditions, as well as KIT-ADC, an antibody-drug conjugate for oncology applications. The company is also engaged in various research programs focused on RTK targets, building on foundational discoveries made in collaboration with leading academic laboratories. As of late 2016, Kolltan Pharmaceuticals operates as a subsidiary of Celldex Therapeutics, Inc.
Spirogen
Private Equity Round in 2009
Spirogen is a clinical-stage biotechnology company focused on developing innovative DNA minor groove-binding molecules with significant therapeutic potential, particularly in cancer treatment. Founded in 2000 and employing a team of 18, Spirogen specializes in modifying naturally occurring antibiotics known as pyrrolobenzodiazepines (PBDs). The company is advancing its research on C2 unsaturated PBD dimers, hydrolysis-activated PBD dimers, and achiral analogs of duocarmycin, which target AT-rich regions of DNA. This technology allows for selective binding and cross-linking at specific sites on cancer cell DNA without altering the overall structure of the DNA helix, presenting new avenues for effective cancer therapies. Spirogen is privately funded and is dedicated to pushing the boundaries of cancer treatment through its specialized molecular technologies.
Kolltan Pharmaceuticals
Series A in 2009
Kolltan Pharmaceuticals, Inc. is a clinical-stage biotechnology company founded in 2007 and based in New Haven, Connecticut. The company specializes in the discovery and development of monoclonal antibody drugs that target receptor tyrosine kinases (RTKs), which play a crucial role in various cancers and other diseases. Its lead product candidate, KTN3379, is an antibody targeting the ErbB3 RTK and is currently undergoing Phase I clinical trials for adult patients with advanced solid tumors. Additionally, Kolltan is developing KTN0158, a KIT RTK inhibitor aimed at treating neurofibromatosis type 1 and other inflammatory conditions, as well as KIT-ADC, an antibody-drug conjugate for oncology applications. The company is also engaged in various research programs focused on RTK targets, building on foundational discoveries made in collaboration with leading academic laboratories. As of late 2016, Kolltan Pharmaceuticals operates as a subsidiary of Celldex Therapeutics, Inc.
Kolltan Pharmaceuticals
Series A in 2008
Kolltan Pharmaceuticals, Inc. is a clinical-stage biotechnology company founded in 2007 and based in New Haven, Connecticut. The company specializes in the discovery and development of monoclonal antibody drugs that target receptor tyrosine kinases (RTKs), which play a crucial role in various cancers and other diseases. Its lead product candidate, KTN3379, is an antibody targeting the ErbB3 RTK and is currently undergoing Phase I clinical trials for adult patients with advanced solid tumors. Additionally, Kolltan is developing KTN0158, a KIT RTK inhibitor aimed at treating neurofibromatosis type 1 and other inflammatory conditions, as well as KIT-ADC, an antibody-drug conjugate for oncology applications. The company is also engaged in various research programs focused on RTK targets, building on foundational discoveries made in collaboration with leading academic laboratories. As of late 2016, Kolltan Pharmaceuticals operates as a subsidiary of Celldex Therapeutics, Inc.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.